Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies

详细信息    查看全文

• 作者：Jessica Salmen (1)
  Julia Neugebauer (2)
  Peter A. Fasching (12) (13) (3)
  Lothar Haeberle (3)
  Jens Huober (1)
  Achim W枚ckel (14)
  Claudia Rauh (3)
  Florian Schuetz (4)
  Tobias Weissenbacher (2)
  Bernd Kost (2)
  Elmar Stickeler (5)
  Maximilian Klar (5)
  Marzenna Orlowska-Volk (6)
  Marisa Windfuhr-Blum (7)
  Joerg Heil (4)
  Joachim Rom (4)
  Christof Sohn (4)
  Tanja Fehm (11) (8)
  Svjetlana Mohrmann (8)
  Christian R. Loehberg (3)
  Alexander Hein (3)
  Ruediger Schulz-Wendtland (10)
  Andreas D. Hartkopf (11)
  Sara Y. Brucker (11)
  Diethelm Wallwiener (11)
  Klaus Friese (2)
  Arndt Hartmann (9)
  Matthias W. Beckmann (3)
  Wolfgang Janni (1)
  Brigitte Rack (2)
  
• 关键词：Progesterone receptor ; Breast cancer ; Prognosis ; Interaction
• 刊名：Breast Cancer Research and Treatment
• 出版年：2014
• 出版时间：November 2014
• 年：2014
• 卷：148
• 期：1
• 页码：143-151
• 全文大小：492 KB
• 参考文献：1. Eisemann N, Waldmann A, Katalinic A (2013) Epidemiology of Breast Cancer - Current Figures and Trends. Geburtsh Frauenheilk 73(2):130鈥?35. doi:10.1055/s-0032-1328075 CrossRef
  2. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206鈥?223. doi:10.1093/annonc/mdt303 CrossRef
  3. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973鈥?979. doi:10.1200/JCO.2003.09.099 CrossRef
  4. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29(32):4273鈥?278. doi:10.1200/JCO.2010.31.2835 CrossRef
  5. Obr AE, Edwards DP (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357(1鈥?):4鈥?7. doi:10.1016/j.mce.2011.10.030 CrossRef
  6. Ismail PM, Li J, DeMayo FJ, O鈥橫alley BW, Lydon JP (2002) A novel LacZ reporter mouse reveals complex regulation of the progesterone receptor promoter during mammary gland development. Mol Endocrinol 16:2475鈥?489 CrossRef
  7. Shyamala G, Chou YC, Louie SG, Guzman RC, Smith GH, Nandi S (2002) Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging. J Steroid Biochem Mol Biol 80:137鈥?48 CrossRef
  8. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98鈥?02. doi:10.1038/nature09387 CrossRef
  9. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R (2010) Progesterone induces adult mammary stem cell expansion. Nature 465(7299):803鈥?07. doi:10.1038/nature09091 CrossRef
  10. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299):798鈥?02. doi:10.1038/nature09027 CrossRef
  11. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107(7):2989鈥?994. doi:10.1073/pnas.0915148107 CrossRef
  12. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103(1):41鈥?0 CrossRef
  13. Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, Allred DC, McCarthy M, Ullrich RL (2002) Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J 16:881鈥?83
  14. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J (2003) Hormone dependence in premalignant mammary progression. Cancer Res 63:1067鈥?072
  15. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509鈥?18. doi:10.1200/JCO.2009.23.1274 CrossRef
  16. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771鈥?84. doi:10.1016/S0140-6736(11)60993-8 CrossRef
  17. Luftner D, Lux MP, Maass N, Schutz F, Schwidde I, Fasching PA, Fehm T, Janni W, Kummel S, Kolberg HC (2012) Advances in Breast Cancer - Looking Back over the Year. Geburtsh Frauenheilk 72(12):1117鈥?129. doi:10.1055/s-0032-1328084 CrossRef
  18. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M (2005) Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: an Hypothesis-Generating Study. J Clin Oncol 23:7512鈥?517 CrossRef
  19. Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van Gils CH, van der Wall E, van Diest PJ (2012) Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases. Cancer. doi:10.1002/cncr.27518
  20. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EG, van der Wall E, van Diest PJ (2010) Receptor conversion in distant breast cancer metastases. Breast Cancer Res 12(5):R75. doi:10.1186/bcr2645 CrossRef
  21. Harrell FE Jr, Lee KL, Pollock BG (1988) Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst 80(15):1198鈥?202 CrossRef
  22. Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11(16):2093鈥?109 CrossRef
  23. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69(6):979鈥?85 CrossRef
  24. Grambsch PM, Therneau TM (1994) Proportional Hazards Tests and Diagnostics Based on Weighted Residuals. Biometrika 81(3):515鈥?26 CrossRef
  25. Chambless LE, Diao G (2006) Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med 25(20):3474鈥?486. doi:10.1002/sim.2299 CrossRef
  26. Gronnesby JK, Borgan O (1996) A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal 2(4):315鈥?28 CrossRef
  27. Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO (2010) Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 119(1):53鈥?1. doi:10.1007/s10549-009-0318-0 CrossRef
  28. Yang LH, Tseng HS, Lin C, Chen LS, Chen ST, Kuo SJ, Chen DR (2012) Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. J Breast Cancer 15(3):288鈥?95. doi:10.4048/jbc.2012.15.3.288 CrossRef
  29. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25(30):4772鈥?778. doi:10.1200/JCO.2007.12.2747 CrossRef
  30. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M (2012) Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol. doi:10.1093/annonc/mds430
  31. Rosen JM (2003) Hormone receptor patterning plays a critical role in normal lobuloalveolar development and breast cancer progression. Breast Dis 18:3鈥?
  32. Brisken C, Rajaram RD (2006) Alveolar and lactogenic differentiation. J Mammary Gland Biol Neoplasia 11(3鈥?):239鈥?48. doi:10.1007/s10911-006-9026-0 CrossRef
  33. Brisken C (2002) Hormonal control of alveolar development and its implications for breast carcinogenesis. J Mammary Gland Biol Neoplasia 7(1):39鈥?8. doi:10.1023/A:1015718406329 CrossRef
  34. Anderson E (2002) The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4(5):197鈥?01 CrossRef
  35. Shoker BS, Jarvis C, Clarke RB, Anderson E, Munro C, Davies MP, Sibson DR, Sloane JP (2000) Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 53(10):778鈥?83 CrossRef
  36. Sutherland RL, Prall OW, Watts CK, Musgrove EA (1998) Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 3(1):63鈥?2. doi:10.1023/A:1018774302092 CrossRef
  37. Skildum A, Faivre E, Lange CA (2005) Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 19(2):327鈥?39. doi:10.1210/me.2004-0306 CrossRef
  38. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB (1997) Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 11(11):1593鈥?607 CrossRef
  39. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, Reddel RR, Clarke CL (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150(7):3318鈥?326. doi:10.1210/en.2008-1630 CrossRef
  40. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790鈥?00. doi:10.1056/NEJMra0801289 CrossRef
  41. Strehl JD, Wachter DL, Fasching PA, Beckmann MW, Hartmann A (2011) Invasive Breast Cancer: recognition of Molecular Subtypes. Breast Care (Basel) 6(4):258鈥?64. doi:10.1159/000331339
  42. Schmidt M, Fasching PA, Beckmann MW, Kolbl H (2012) Biomarkers in Breast Cancer鈥揳n Update. Geburtsh Frauenheilk 72(9):819鈥?32. doi:10.1055/s-0032-1315340 CrossRef
  43. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784鈥?795. doi:10.1200/JCO.2009.25.6529 CrossRef
  
• 作者单位：Jessica Salmen (1)
  Julia Neugebauer (2)
  Peter A. Fasching (12) (13) (3)
  Lothar Haeberle (3)
  Jens Huober (1)
  Achim W枚ckel (14)
  Claudia Rauh (3)
  Florian Schuetz (4)
  Tobias Weissenbacher (2)
  Bernd Kost (2)
  Elmar Stickeler (5)
  Maximilian Klar (5)
  Marzenna Orlowska-Volk (6)
  Marisa Windfuhr-Blum (7)
  Joerg Heil (4)
  Joachim Rom (4)
  Christof Sohn (4)
  Tanja Fehm (11) (8)
  Svjetlana Mohrmann (8)
  Christian R. Loehberg (3)
  Alexander Hein (3)
  Ruediger Schulz-Wendtland (10)
  Andreas D. Hartkopf (11)
  Sara Y. Brucker (11)
  Diethelm Wallwiener (11)
  Klaus Friese (2)
  Arndt Hartmann (9)
  Matthias W. Beckmann (3)
  Wolfgang Janni (1)
  Brigitte Rack (2)
  
  1. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
  2. Department of Gynecology and Obstetrics, Campus Innenstadt University Hospital, Ludwig Maximilian University, Munich, Germany
  12. Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, USA
  13. Department of Gynecology and Obstetrics, Comprehensive Cancer Center EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen鈥揘uremberg, Erlangen, Germany
  3. University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Germany
  14. Department of Gynecology and Obstetrics, W眉rzburg University Hospital, W眉rzburg, Germany
  4. Department of Gynecology and Obstetrics, Breast Unit, Heidelberg University Hospital, Heidelberg, Germany
  5. Department of Obstetrics and Gynecology, Freiburg University Medical Center, Freiburg, Germany
  6. Institute of Pathology, Freiburg University Medical Center, Freiburg, Germany
  7. Department of Radiology, Freiburg University Medical Center, Freiburg, Germany
  11. Department of Gynecology and Obstetrics, University Hospital T眉bingen, T眉bingen, Germany
  8. Department of Gynecology and Obstetrics, Duesseldorf University Hospital, Duesseldorf, Germany
  10. Institute of Diagnostic Radiology, University Breast Center, Erlangen University Hospital, Erlangen, Germany
  9. Institute of Pathology, University Breast Center, Erlangen University Hospital, Erlangen, Germany
  
• ISSN：1573-7217

文摘

The progesterone receptor (PR) has been increasingly well described as an important mediator of the pathogenesis and progression of breast cancer. The aim of this study was to assess the role of PR status as a prognostic factor in addition to other well-established prognostic factors. Data from five independent German breast cancer centers were pooled. A total of 7,965 breast cancer patients were included for whom information about their PR status was known, as well as other patient and tumor characteristics commonly used as prognostic factors. Cox proportional hazards models were built to compare the predictive value of PR status in addition to age at diagnosis, tumor size, nodal status, grading, and estrogen receptor (ER) status. PR status significantly increased the accuracy of prognostic predictions with regard to overall survival, distant disease-free survival, and local recurrence-free survival. There were differences with regard to its prognostic value relative to subgroups such as nodal status, ER status, and grading. The prognostic value of PR status was greatest in patients with a positive nodal status, negative ER status, and low grading. The PR-status adds prognostic value in addition to ER status and should not be omitted from clinical routine testing. The significantly greater prognostic value in node-positive and high-grade tumors suggests a greater role in the progression of advanced and aggressive tumors.